Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies
Vaccine, Volume 25, No. 19, Year 2007
Notification
URL copied to clipboard!
Description
Estimates of minimum protective antibody concentrations for vaccine preventable diseases are of critical importance in assessing whether new vaccines will be as effective as those for which clinical efficacy was shown directly. We describe a method for correlating pneumococcal anticapsular antibody responses of infants immunized with pneumococcal conjugate (PnC) vaccine (Prevenar) with clinical protection from invasive pneumococcal disease (IPD). Data from three double blind controlled trials in Northern Californian, American Indian and South African infants were pooled in a meta-analysis to derive a protective concentration of 0.35 μg/ml for anticapsular antibodies to the 7 serotypes in Prevenar. This concentration has been recommended by a WHO Working Group as applicable on a global basis for assessing the efficacy of future pneumococcal conjugate vaccines. The WHO Working Groups anticipated that modifications in antibody assays for pneumococcal anticapsular antibodies would occur. The principles for determining whether such assay modifications should change the protective concentration are outlined. These principles were applied to an improvement in the ELISA for anticapsular antibodies, i.e. absorption with 22F pneumococcal polysaccharide, which increases the specificity of the assay for vaccine serotype anticapsular antibodies by removing non-specific antibodies. Using sera from infants in the pivotal efficacy trial in Northern California Kaiser Permanente (NCKP), 22F absorption resulted in minimal declines in pneumococcal antibody in Prevenar immunized infants but significant declines in unimmunized controls. Recalculation of the protective concentration after 22F absorption resulted in only a small decline from 0.35 μg/ml to 0.32 μg/ml. These data support retaining the 0.35 μg/ml minimum protective concentration recommended by WHO for assessing the efficacy of pneumococcal conjugate vaccines in infants. © 2007 Elsevier Ltd. All rights reserved.
Authors & Co-Authors
Siber, George R.
United States, Pearl River
Pfizer Research Pearl River
Chang, Ih
Switzerland, Basel
Novartis International ag
Baker, Sherryl A.
United States, Pearl River
Pfizer Research Pearl River
Fernsten, Philip
United States, Pearl River
Pfizer Research Pearl River
O'Brien, Katherine L.
United States, Baltimore
Johns Hopkins Bloomberg School of Public Health
Santosham, Mathuram
United States, Baltimore
Johns Hopkins Bloomberg School of Public Health
Klugman, K. P.
United States, Atlanta
Rollins School of Public Health
South Africa, Johannesburg
University of the Witwatersrand
Madhi, Shabir A.
South Africa, Johannesburg
University of the Witwatersrand
Paradiso, Peter
United States, Pearl River
Pfizer Research Pearl River
Kohberger, Robert C.
Unknown Affiliation
Statistics
Citations: 315
Authors: 10
Affiliations: 5
Identifiers
Doi:
10.1016/j.vaccine.2007.01.119
ISSN:
0264410X
Research Areas
Disability
Study Approach
Systematic review